Fairvalue-Calculator Fairvalue-Calculator
EN DE

Arcadia Biosciences, Inc (RKDA) Fair Value & Analysis

Consumer Defensive · US · Market cap $1.5M

Price$0.6705
Fair Value$1.92
Upside+186.4%
Quality95/100
Evidence: Low Range $1.27 – $2.40

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Arcadia Biosciences, Inc (RKDA) currently trades at $0.6705, while our model-based Fair Value estimate is $1.92 — implying the stock looks roughly 186.4% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Arcadia Biosciences, Inc (RKDA) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $1.92 versus a price of $0.6705 — about +186% (undervalued). Model-based estimate, not financial advice.
What is the fair value of RKDA?
Our 21-model fair value for Arcadia Biosciences, Inc is $1.92 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.6705.
What is the quality score of RKDA?
Arcadia Biosciences, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.